華潤雙鶴(600062.SH):肝素鈉原料藥獲得化學原料藥上市申請批准通知書
格隆匯1月8日丨華潤雙鶴(600062.SH)公佈,控股子公司東營天東製藥有限公司肝素鈉原料藥收到了國家藥品監督管理局下發的《化學原料藥上市申請批准通知書》。肝素鈉(HeparinSodium),是一種抗凝血藥,用於預防血栓形成和栓塞,如深部靜脈血栓、心肌梗死、肺栓塞、血栓性靜脈炎及術後血栓形成等。治療各種原因引起的彌散性血管內凝血(DIC),如細菌性膿毒血癥、胎盤早期剝離、惡性腫瘤細胞溶解所致的DIC,但蛇咬傷所致的DIC除外。早期應用可防止纖維蛋白原和其他凝血因子的消耗。也可用於其他體內外抗凝血,如心導管檢查、心臟手術體外循環、血液透析等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.